Skip to main content
OpenTrials
Completed

NCT Number: NCT07234240

Blinded Consumer Study for the Evaluation of the Usability and Efficacy of One Medical Device in Venous Return

The primary goal of this study was to assess, in vivo, the efficacy of the medical device Invisible insoles LIGHT LEGS in improving venous return in subjects affected by this problem after 14 days of medical device use, by self-assessment, filling in questions regarding Quality of Life, in comparison to the baseline.

The secondary goals of this study were (1) to assess in vivo the perception of subjects about the rapid relief felt after 7 days of using the same medical device, by selfassessment, filling-in three subjective evaluation questions, and (2) to assess in vivo the usability of the subjects regarding the same medical device after 14 days of its use, by self-assessment, filling in subjective evaluation questions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Venous Disease Pathological Conditions, Signs and Symptoms Quality of Life Signs and Symptoms Symptoms and Signs

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Juliana Gouveia

Porto, Portugal

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Gender: Female/Male;
  • Age: with 18 years old and older;
  • Having signed an Informed Consent Form (ICF);
  • Willingness, ability and likeliness to comply with all the study procedures and restrictions;
  • Ability to give informed consent;
  • Available during the entire study period;
  • Understanding Portuguese language: Portuguese-speaking subjects capable of reading the documents;
  • Affected by a symptomatic venous return problem;
  • With a score >14 from the question 1 to 11 of the adapted CIVIQ questionnaire (each question scored on a scale from 0 to 4);
  • Agree to wear open shoes suitable for insoles throughout the study, for at least 8 hours per day (with a heel <5cm);
  • Having a shoe size of 36 to 41;

Exclusion criteria

  • Known allergy or known history of hypersensitivity to the components of the investigational device and related compounds;
  • Currently participating in another clinical study that may interfere with the study;
  • Diagnosed skin diseases and/or cutaneous alterations on the test region (feet) that may impair the study (for example tattoos, marks, burns, scars, etc.);
  • Diagnosed diseases that may impair the study (including but not limited to: Diabetes, Arteritis, Phlebitis, etc);
  • Under pharmacological treatments on the 30 days previous to the beginning of the study and during the entire period of the study that may impair it (including but not limited to: inflammatory drugs, any drug that might cover the signs and symptoms, drugs with arterial or venous indications, etc.);
  • Having applied any type of topical product (pharmaceutical, cosmetic or other) with similar effect of the medical device under study, on the test region (feet) during the study, besides the investigational device;
  • Having a stage of CVD C3 on the CEAP classification;
  • Having had a traumatic or neurological history in the last 6 months;
  • Wearing an orthopaedic insole made by a health professional;
  • Having a significant and disabling lower limb pain;
  • Having a significant and disabling back pain;
  • Having a contraindication to wearing insoles and open shoes;
  • Wearing open shoes with an anatomical shape (e.g. Birkenstock);
  • Pregnancy or intention to conceive during the study;
  • Breast-feeding.

Treatment and study plan

Insoles

Device

Insoles At Day 0, the patient received the insoles and adapted them to his open shoes. The patient filled the quality-of-life's questionnaire at Day 0 and the same at Day14. The patient filled the rapid relief's questionnaire at Day7 and a usability's questionnaire at Day14.

Primary outcomes

  1. Quality of Life

    Time frame: Day 0 and Day 14

    CIVIQ (ChronIc Venous Insufficiency Quality of Life Questionnaire) 20 : It is a quality of life assessment scale comprising 20 items grouped into four main dimensions (pain, physical, psychological, social) with 5 levels (0 point (min) to 4 points (max)).The final score is between 0 and 80 points. A low score indicates a low impact of the disease on quality of life.

Secondary outcomes

  1. Rapid relief

    Time frame: Day 7

    Perception of subjects about the rapid relief felt after 7 days (t7) of using the medical device, by self-assessment, filling-in three subjective evaluation questions

  2. Usability evaluation

    Time frame: Day 14

    Usability of the subjects regarding the same device, through subjective evaluation questions filled by the subjects after 14 days (D14) of using the medical device.

Sponsors and collaborators

Lead sponsor

Millet Innovation

Industry

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Nov 18, 2025
Registry last updated
Nov 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.